Literature DB >> 12754708

De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy.

Lieve Claes1, Berten Ceulemans, Dominique Audenaert, Katrien Smets, Ann Löfgren, Jurgen Del-Favero, Sirpa Ala-Mello, Lina Basel-Vanagaite, Barbara Plecko, Salmo Raskin, Paul Thiry, Nicole I Wolf, Christine Van Broeckhoven, Peter De Jonghe.   

Abstract

Severe myoclonic epilepsy of infancy (SMEI or Dravet syndrome) is a rare disorder occurring in young children often without a family history of a similar disorder. The earliest disease manifestations are usually fever-associated seizures. Later in life, patients display different types of afebrile seizures including myoclonic seizures. Arrest of psychomotor development occurs in the second year of life and most patients become ataxic. Patients are resistant to antiepileptic drug therapy. Recently, we described de novo mutations of the neuronal sodium channel alpha-subunit gene SCN1A in seven isolated SMEI patients. To investigate the contribution of SCN1A mutations to the etiology of SMEI, we examined nine additional SMEI patients. We observed eight coding and one noncoding mutation. In contrast to our previous study, most mutations are missense mutations clustering in the S4-S6 region of SCN1A. These findings demonstrate that de novo mutations in SCN1A are a major cause of isolated SMEI. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754708     DOI: 10.1002/humu.10217

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  52 in total

Review 1.  Autosomal dominant nocturnal frontal lobe epilepsy--a critical overview.

Authors:  Romina Combi; Leda Dalprà; Maria Luisa Tenchini; Luigi Ferini-Strambi
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

2.  novoSNP, a novel computational tool for sequence variation discovery.

Authors:  Stefan Weckx; Jurgen Del-Favero; Rosa Rademakers; Lieve Claes; Marc Cruts; Peter De Jonghe; Christine Van Broeckhoven; Peter De Rijk
Journal:  Genome Res       Date:  2005-03       Impact factor: 9.043

Review 3.  Sodium channel mutations in epilepsy and other neurological disorders.

Authors:  Miriam H Meisler; Jennifer A Kearney
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

4.  Fast pseudo-periodic oscillation in the rat brain voltage-gated sodium channel alpha subunit.

Authors:  S Majumdar; S K Sikdar
Journal:  J Membr Biol       Date:  2005-11       Impact factor: 1.843

5.  Scn2a sodium channel mutation results in hyperexcitability in the hippocampus in vitro.

Authors:  Kara Buehrer Kile; Nan Tian; Dominique M Durand
Journal:  Epilepsia       Date:  2007-11-21       Impact factor: 5.864

Review 6.  The state of the art in the genetic analysis of the epilepsies.

Authors:  David A Greenberg; Deb K Pal
Journal:  Curr Neurol Neurosci Rep       Date:  2007-07       Impact factor: 5.081

7.  Temperature- and age-dependent seizures in a mouse model of severe myoclonic epilepsy in infancy.

Authors:  John C Oakley; Franck Kalume; Frank H Yu; Todd Scheuer; William A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

8.  Sleep impairment and reduced interneuron excitability in a mouse model of Dravet Syndrome.

Authors:  Franck Kalume; John C Oakley; Ruth E Westenbroek; Jennifer Gile; Horacio O de la Iglesia; Todd Scheuer; William A Catterall
Journal:  Neurobiol Dis       Date:  2015-03-10       Impact factor: 5.996

Review 9.  Genetics of the epilepsies: where are we and where are we going?

Authors:  Ingo Helbig; Daniel H Lowenstein
Journal:  Curr Opin Neurol       Date:  2013-04       Impact factor: 5.710

10.  A novel variant in the 3' UTR of human SCN1A gene from a patient with Dravet syndrome decreases mRNA stability mediated by GAPDH's binding.

Authors:  Tao Zeng; Zhao-Fei Dong; Shu-Jing Liu; Rui-Ping Wan; Ling-Jia Tang; Ting Liu; Qi-Hua Zhao; Yi-Wu Shi; Yong-Hong Yi; Wei-Ping Liao; Yue-Sheng Long
Journal:  Hum Genet       Date:  2014-01-25       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.